Contineum Pharma - CTNM EV/EBITDA Multiple

Corporate emblem and logo of Contineum Pharma (CTNM)

The price history of Contineum Therapeutics, Inc. (CTNM) reflects the valuation dynamics of a biopharmaceutical business targeting fibrosis and multiple sclerosis via LPA1 receptors, where the EV/EBITDA ratio stands at 0.00. The company's resilience is bolstered by alliances with global behemoths, although success depends on the final trials of new molecules. Drug development is automated using algorithms, yet medical supervision of patients remains a priority.

CTNM (Contineum Pharma) EV/EBITDA Multiple history from 11/23/2025 to 11/15/2026

CTNM (Contineum Therapeutics Inc): analytical breakdowns and indicator data

Summary company analytics:CTNM (Contineum Therapeutics Inc)
Original product of Contineum Therapeutics

Investments in PhD-level R&D personnel drive the EV/EBITDA ratio dynamics for the capital-intensive business of Contineum Therapeutics (CTNM). This metric compares the total enterprise value with its operating profit before depreciation, taxes, and interest. A decline in this indicator signals strengthening cash flow and a reduction in debt risks. For an investor, such a trajectory represents an increase in the efficiency of capital expenditures on neurobiological developments.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jazz Pharmaceuticals plc JAZZ|CYTK: Enterprise Value to Operating Income Before Depreciation|PTC Bio - EV/EBITDA Multiple|Company Value to EBITDA Scholar Rock Corp|CNTA (Centessa Pharmaceuticals plc) - Enterprise Value to EBITDA Ratio|Dyne Corp - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Edgewise Therapeutics|RAPP: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alumis Pharma (ALMS)|ZVRA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Larimar Pharma LRMR|Capricor Therapeutics - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRDA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Channel Therapeutics|MNOV: EV/EBITDA Multiple|Company Value to EBITDA Serina Therapeutics Inc (SER)|Enterprise Value to EBITDA Ratio BTAI|promisneurosciences.com - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple APUS|EV/EBITDA Multiple AEON Biopharma, Inc. (AEON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NLS Pharma NLSP|Total Company Value to Operating Income Before Depreciation Ratio Bionomics Limited (BNOX)|FSD Pharma Inc. - EV/EBITDA Multiple|RETA - EV/EBITDA Multiple